Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

49.85 -0.55 (-1.09%)
Streaming Delayed Price Updated: 3:59 PM EDT, Apr 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
36 37 Next >
News headline image
The Daily Biotech Pulse: Roche's Lung Cancer Combo Therapy Flunks Late-Stage Study, Adagio Spikes On Positive COVID Antibody Data, Amylyx Awaits Adcom Verdict ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
Genentech Provides Update on Phase III SKYSCRAPER-02 Study in Extensive-Stage Small Cell Lung Cancer
From Genentech
Via Business Wire
News headline image
Biotech Funds and ETFs Continue to Lag ↗
It’s no secret that market sectors driving inflation are leading the market. With the US economy still strong and the War in Ukraine limiting supply of nat gas and raw materials, producer costs are... 
Via Talk Markets
News headline image
Why Are ImmunoGen Shares Trading Lower Today ↗
ImmunoGen Inc (NASDAQ: IMGN)  
Via Benzinga
News headline image
Drug makers, Scientists Working For Long COVID Treatments: Reuters ↗
Researchers and drugmakers, including those who have launched antiviral pills and monoclonal antibodies for COVID-19, are having early discussions about targeting Long COVID,  
Via Benzinga
News headline image
The Daily Biotech Pulse: MEI Pharma Wilts On Adverse Regulatory Development, Decision Day For Zogenix, AN2 Therapeutics IPO ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
Flood Helping Ukraine ↗
Emerging markets are gaining as mature markets look risky. 
Via Talk Markets
News headline image
How Rivals Merck, Bristol Myers Benefit From Eli Lilly's FDA Snag ↗
The Food and Drug Administration on Thursday rejected a lung cancer drug Eli Lilly tested only in China, but LLY stock inched higher. 
Via Investor's Business Daily
News headline image
Up On Bad News ↗
Despite the plane crash in China, Boeing's stock is up today. 
Via Talk Markets
News headline image
World Markets News For Friday ↗
Buoyant global markets are closing the week and one good performer, Vir Biotech, today gained an impressive 6.09%. 
Via Talk Markets
News headline image
Roche's Evrysdi Shows Long-Term Efficacy, Safety In Broader Spinal Muscular Atrophy Population ↗
 
Via Benzinga
News headline image
Apellis Pharma Nears Breakout As Biotech Plots Its Blockbuster Filing ↗
If approved, this would be the company's second drug to hit the U.S. market. 
Via Investor's Business Daily
News headline image
New Data for Genentech’s Evrysdi (risdiplam) Demonstrate Long-Term Efficacy and Safety in a Broad Population of People With Spinal Muscular Atrophy (SMA)
From Genentech
Via Business Wire
News headline image
The OTCQX's Top 10 Experience A Shuffle In February ↗
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga
News headline image
The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Exelixis Will Not Pursue Untreated Liver Cancer Indication For Cabometyx Combo Therapy ↗
Exelixis Inc (NASDAQ: EXEL) announced results from the final analysis of the second primary endpoint of overall survival (OS) from the phase 3 COSMIC-312 trial of Cabometyx (cabozantinib) plus... 
Via Benzinga
News headline image
Hopes For A Peace Accord ↗
The winner today was BioNTech up 14.89% on hopes for new sales for the Covid-19 variant. 
Via Talk Markets
News headline image
Biogen Posts New Updates Across its Spinraza SMA Research Program ↗
Biogen Inc (NASDAQ: BIIB) announced new data and updates from its Spinraza (nusinersen) and spinal muscular atrophy (SMA) research program, including the ASCEND, RESPOND and... 
Via Benzinga
News headline image
Vaccine Stocks BioNTech, Moderna Pop On Fourth Dose — But IBD/TIPP Poll Says Few People Care ↗
The IBD/TIPP Poll shows Covid has fallen among Americans' priorities. 
Via Investor's Business Daily
News headline image
OTC Markets 2021 Annual Data Review Highlights A Record 60% $ Volume Increase ↗
Photo by Sophie Bakes on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. The... 
Via Benzinga
News headline image
The Ruble Is Rubble ↗
MSCI says Russian companies are 
Via Talk Markets
News headline image
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings ↗
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments... 
Via Benzinga
News headline image
Holiday Over ↗
China is busily avoiding taking sides between Ukraine and Russia. 
Via Talk Markets
News headline image
Roche And AstraZeneca Settle Ultomiris Patent Lawsuit ↗
Roche Holdings AG (OTC: RHHBY) has decided to close out a patent infringement lawsuit against AstraZeneca plc (NASDAQ: AZN), centering around the latter's newly... 
Via Benzinga
News headline image
Sanofi-Regeneron's Dupixent Falls Short In Chronic Spontaneous Urticaria Trial ↗
Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have reported disappointing results from the Phase 3 trial of Dupixent (dupilumab... 
Via Benzinga
News headline image
Biotech Stocks Are Down And Out; Can These 2022 Trends Save Them? ↗
Can the formerly red-hot biotech segment return to its previous glory? 
Via Investor's Business Daily
News headline image
Large Cap Biopharma- Well Positioned For Choppy Markets ↗
If the past week is any indicator large-cap biopharma stocks are a good place to hide from the turbulence of 2022 markets. 
Via Talk Markets
News headline image
These OTC Securities Reported The Most Trading Volume In January – With Possible Sustained Interest In International Operators ↗
Photo from Jason Briscoe on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga
News headline image
Can Anyone Challenge Pfizer's Covid Dominance? Why These Biotechs Say Yes ↗
Drug behemoth Pfizer was the first to launch a Covid antiviral pill — but a pack of small biotech stocks are already nipping at its heels. 
Via Investor's Business Daily
News headline image
New Two-Year Data for Genentech’s Vabysmo and Susvimo Reinforce Potential to Maintain Vision With Fewer Treatments for People With Two Leading Causes of Vision Loss
From Genentech
Via Business Wire
< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
36 37 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.